{"preliminary_commentary":{"by_channel":{"x_thread":32,"podcast":6,"youtube":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05933577\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"INTerpath-001","nct_id":"NCT05933577","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=interpath-001-nct05933577. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive up to 9 doses of intismeran autogene via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.","label":"Intismeran autogene + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive up to 9 doses of dose matched placebo to intismeran autogene via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.","label":"Placebo + Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":["ModernaTX, Inc."],"completion_date":{"date":"2030-09-26","type":"ESTIMATED"},"conditions":["Melanoma"],"enrollment":{"count":1089,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Intismeran autogene","otherNames":["mRNA-4157","Individualized neoantigen therapy","V940"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":["MK-3475","Keytruda®"],"type":"BIOLOGICAL"},{"name":"Placebo","otherNames":["Normal saline","Dextrose"],"type":"OTHER"}],"last_update":"2025-09-24","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-10-26","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recurrence-Free Survival (RFS)","timeFrame":"Up to approximately 74 months"}],"references":[],"start_date":{"date":"2023-07-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)","url":"https://clinicaltrials.gov/study/NCT05933577"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/interpath-001-nct05933577"}